相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
Ahmed Waraky et al.
ONCOTARGET (2014)
Insulin-like growth factor 1 acts as an autocrine factor to improve early embryogenesis in vitro
Charmaine J. Green et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2013)
Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Xuping Wu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells
Satoru Osuka et al.
STEM CELLS (2013)
Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5
Bob Y. Liu et al.
CANCER RESEARCH (2012)
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
Giorgio V. Scagliotti et al.
CANCER TREATMENT REVIEWS (2012)
Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma
Simon Ekman et al.
ACTA ONCOLOGICA (2011)
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry
Yuko Ronquist-Nii et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Development of the Monoclonal Antibody Figitumumab, Targeting the Insulin-like Growth Factor-1 Receptor, for the Treatment of Patients with Non-Small-Cell Lung Cancer
Antonio Gualberto et al.
CLINICAL LUNG CANCER (2009)
Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Antonio Gualberto et al.
CURRENT DRUG TARGETS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
How do anti-mitotic drugs kill cancer cells?
Karen E. Gascoigne et al.
JOURNAL OF CELL SCIENCE (2009)
被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Zhenfeng Duan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
A. Gualberto et al.
ONCOGENE (2009)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1
R. Vasilcanu et al.
ONCOGENE (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Disruption of the insulin-like growth factor type 1 receptor in Osteoblasts enhances insulin signaling and action
Keertik Fulzele et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
A Girnita et al.
CANCER RESEARCH (2004)
分享论文
